Zanubrutinib for the treatment of relapsed/refractory hairy cell leukemia

被引：6
|
作者：
Tam, Constantine S. [1 ,8 ]
Trotman, Judith [2 ,3 ]
Opat, Stephen [4 ,5 ]
Stern, Jennifer C. [6 ]
Allewelt, Heather [6 ]
By, Kunthel [6 ]
Novotny, William [6 ]
Huang, Jane [6 ]
Tedeschi, Alessandra [7 ]
机构：
[1] Monash Univ, Alfred Hosp, Melbourne, Vic, Australia
[2] Concord Repatriat Gen Hosp, Concord, NSW, Australia
[3] Univ Sydney, Concord, NSW, Australia
[4] Monash Hlth, Clayton, Vic, Australia
[5] Monash Univ, Clayton, Vic, Australia
[6] BeiGene, San Mateo, CA USA
[7] ASST Grande Osped Metropolitano Niguarda, Milan, Italy
[8] Alfred Hosp, 55 Commercial Rd, Melbourne, Vic, Australia
来源：
BLOOD ADVANCES | 2023年 / 7卷 / 12期
关键词：
D O I：
10.1182/bloodadvances.2022008990
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2884 / 2887
页数：4
相关论文
共 50 条
  • [31] Bendamustine and Rituximab for the Treatment of Multiply Relapsed Hairy Cell Leukemia
    Kreitman, Robert J.
    Stetler-Stevenson, Maryalice
    Wilson, Wyndham H.
    Jeffrey, Sapolsky
    Roth, Laura
    Arons, Evgeny
    BLOOD, 2011, 118 (21) : 1672 - 1672
  • [32] Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed/Refractory Mantle Cell Evidence to Date
    Sawalha, Yazeed
    Bond, David A.
    Alinari, Lapo
    ONCOTARGETS AND THERAPY, 2020, 13 : 6573 - 6581
  • [33] Zanubrutinib - Relapsed or refractory follicular lymphoma
    Grant-Monlouis-Felicite, Fiona
    Diop, Nadia
    BULLETIN DU CANCER, 2024, 111 (06) : 542 - 544
  • [34] Cost Effectiveness of Zanubrutinib Versus Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
    Kang, Dong-Won
    Wang, Li
    Short, Nicholas J.
    Ferrajoli, Alessandra
    Wang, Yucai
    Zhou, Shouhao
    Shen, Chan
    PHARMACOECONOMICS, 2024, 42 (04) : 409 - 418
  • [35] Treatment of refractory hairy cell leukemia by BRAF-inhibition
    Dietrich, S.
    Pircher, A.
    Andrulis, M. A.
    Peyrade, F.
    Wendtner, C. -M
    Gaehler, A.
    Follows, G.
    Dyer, M.
    Elter, T.
    Zeiser, R.
    Herrmann, M.
    Herold, M.
    Dearden, C.
    Haferlach, T.
    Hallek, M.
    Huellein, J.
    Matutes, E.
    Duerig, J.
    von Kalle, C.
    Glimm, H.
    Froehling, S.
    Abdel-Wahab, O.
    Hutter, B.
    Steurer, M.
    Ho, A.
    Zenz, T.
    Oncology Research and Treatment, 2015, 38 : 119 - 119
  • [36] TREATMENT OF REFRACTORY HAIRY-CELL LEUKEMIA BY BRAF INHIBITION
    Dietrich, S.
    Glimm, H.
    Lehners, N.
    Huellein, J.
    Hundemer, M.
    Jethwa, A.
    Andrulis, M.
    Capper, D.
    Schulte, C.
    Mandel, T.
    Dreger, P.
    Froehling, S.
    von Kalle, C.
    Ho, A.
    Zenz, T.
    HAEMATOLOGICA, 2012, 97 : 63 - 63
  • [37] Cost Effectiveness of Zanubrutinib Versus Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
    Dong-Won Kang
    Li Wang
    Nicholas J. Short
    Alessandra Ferrajoli
    Yucai Wang
    Shouhao Zhou
    Chan Shen
    PharmacoEconomics, 2024, 42 : 409 - 418
  • [38] Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma
    Song, Yuqin
    Zhou, Keshu
    Yang, Shenmiao
    Hu, Jianda
    Zou, Dehui
    Gao, Sujun
    Pan, Ling
    Wang, Tingyu
    Yang, Haiyan
    Zhang, Huilai
    Zhou, Daobin
    Ji, Jie
    Xu, Wei
    Feng, Ru
    Jin, Jie
    Lv, Fangfang
    Huang, Haiwen
    Fan, Xiaosi
    Xu, Sheng
    Zhu, Jun
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (04) : 606 - 616
  • [39] Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experience
    Kaya, Suereyya Yigit
    Mutlu, Yasa Gul
    Malkan, Umit Yavuz
    Mehtap, Ozgur
    Karadag, Fatma Keklik
    Korkmaz, Gulten
    Elverdi, Tugrul
    Saydam, Gueray
    Ozet, Guelsuem
    Ar, Muhlis Cem
    Melek, Elif
    Maral, Senem
    Kaynar, Leylagul
    Sevindik, Omuer Gokmen
    LEUKEMIA RESEARCH, 2024, 140
  • [40] Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma
    Yuqin Song
    Keshu Zhou
    Shenmiao Yang
    Jianda Hu
    Dehui Zou
    Sujun Gao
    Ling Pan
    Tingyu Wang
    Haiyan Yang
    Huilai Zhang
    Daobin Zhou
    Jie Ji
    Wei Xu
    Ru Feng
    Jie Jin
    Fangfang Lv
    Haiwen Huang
    Xiaosi Fan
    Sheng Xu
    Jun Zhu
    Investigational New Drugs, 2023, 41 : 606 - 616
12345